• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CHM
Click for more information
0.00% 0.9¢

CHIMERIC THERAPEUTICS LIMITED - News & Media

Market Cap $8.776M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company.... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.More

Articles & Videos

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.

07 Oct 2024 11:17 (AEDT)

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

08 Feb 2024 13:19 (AEDT)

Chimeric Therapeutics announces positive preclinical data for CHM 1301

Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company's next-generation CLTX CAR NK cell therapy program.

23 Nov 2023 12:53 (AEDT)

Chimeric Therapeutics to raise $10m through entitlement offer

Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.

25 Oct 2023 13:11 (AEDT)

Chimeric Therapeutics (ASX:CHM) completes dose escalation in phase 1A brain cancer trial

Chimeric Therapeutics (ASX:CHM) has treated the third patient participating in its phase 1A dose escalation study at the City of Hope Hospital in California.

29 Aug 2023 14:54 (AEST)



(20min delay)
Last
0.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.776M
Open High Low Value Volume
1.0¢ 1.0¢ 0.9¢ $9.73K 1.077M

Buyers (Bids)

No. Vol. Price($)
22 5624045 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 3249484 8
View Market Depth
Last trade - 14.35pm 01/11/2024 (20 minute delay) ?
Last
1.0¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
0.9¢ 1.0¢ 0.9¢ 316932
Last updated 14.55pm 01/11/2024 ?
CHM (ASX) Chart

Top Stories

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Headline inflation in Australia has fallen to 2.8%, and that officially takes us into the RBA's 2-3% inflation target band. But...
'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers Nickel-rich Indonesia muscles in on Australian graphite producers as the Southeast Asian country expands into downstream industries.
Palladium's the newest geopolitical hot commodity. But ASX exposure is limited On October 24, the USA reportedly approached its G7 counterparts and proposed a ban on Russian titanium, and, palladium.
Making money: How many microcaps should be in an investor's portfolio? In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor portfolio.
What each US election outcome would mean for Australian companies & investors We all know that what happens in the US ripples down to impact Australia. Next week’s US presidential elections will be a major catalyst…
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.